New York, NY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bowen Acquisition Corp (NASDAQ: BOWN) (“BOWN”), a special purpose acquisition company, announced the execution of an agreement and plan of merger (the “Merger Agreement”) with Shenzhen Qianzhi BioTechnology Co., Ltd (“Qianzhi BioTech”), a biotech company engaged in development, manufacturing and sales of ozonated health and wellness products in China.

2024年1月18日，纽约（环球通讯社）--Bowen Acquisition Corp（NASDAQ:BOWN）（“BOWN”）是一家特殊目的收购公司，宣布与从事开发的生物技术公司深圳乾智生物技术有限公司（“乾智生物技术”）签署协议和合并计划（“合并协议”），臭氧保健品在中国的生产和销售。

Pursuant to the Merger Agreement, BOWN’s wholly owned subsidiary, Bowen Merger Sub, a Cayman Islands exempted company, will merge (the “Merger” or the “Business Combination”) with and into Qianzhi Group Holding (Cayman) Limited, parent of Qianzhi BioTech and an exempted company incorporated with limited liability in the Cayman Islands (“NewCo”), with NewCo being the surviving company of the Merger and becoming a wholly-owned subsidiary of BOWN.

根据合并协议，BOWN的全资子公司Bowen merge Sub（一家开曼群岛豁免公司）将与前智集团控股（开曼）有限公司合并（“合并”或“企业合并”），前智集团控股（开曼）有限公司是前智生物科技的母公司，也是一家在开曼群岛注册成立的豁免有限责任公司（“NewCo”），NewCo是合并中幸存的公司，并成为BOWN的全资子公司。

In connection with the Merger, the NewCo Shareholders will receive an aggregate of 7,246,377 ordinary shares of BOWN and have the right to receive up to an additional 1,400,000 ordinary shares of BOWN upon the achievement of certain earnout targets as provided for in the Merger Agreement. The transaction has been approved by the boards of directors of both BOWN and Qianzhi BioTech and is expected to be consummated in the second or third quarter of 2024, subject to regulatory and stockholder approval by the stockholders of BOWN and NewCo and the satisfaction of certain other customary closing conditions.

就合并而言，NewCo股东将获得总计7246377股BOWN普通股，并有权在达到合并协议规定的某些盈利目标后，再获得多达1400000股BOWN普通股。该交易已获得BOWN和Qianzhi BioTech董事会的批准，预计将于2024年第二或第三季度完成，但须经BOWN和NewCo股东的监管和股东批准，并满足某些其他惯例交割条件。

The majority shareholder of NewCo has agreed to vote in favor of the Merger. Qianzhi BioTech, based in Shenzhen, China, is a health and wellness focused biotech company and an early adopter and developer of plant-based and ozonated products for antibacterial, skincare, gynecological and andrological applications.

NewCo的大股东同意投票支持合并。总部位于中国深圳的千智生物科技是一家专注于健康和保健的生物技术公司，是抗菌、护肤、妇科和男科应用的植物和臭氧产品的早期采用者和开发者。

The majority of Qianz.

羌族的大多数。